Gabapentin Dementia Link: New Study Reveals 22% Higher Risk for Chronic Pain Patients

New Study Links Nerve Pain Drug Gabapentin to Increased Dementia and Cognitive Decline

My spine seized at the thought. I was three years into my own gabapentin cycle. 900mg nightly for sciatica, prescribed by a well-meaning GP who called it "low risk." The NHS prescribes this drug to over a million patients annually for nerve pain conditions like fibromyalgia. Diabetic neuropathy, and the kind of back pain that keeps you awake at 3am. Now a major new observational study has linked gabapentin to a risk of dementia and cognitive decline.

The study, published in Neurology and analysing real-world data from over 700,000 UK patients, found that those taking gabapentin had a markedly higher chance of developing dementia compared to non-users. This isn't speculation from animal models or small trials. This is population-level evidence from the very same prescribing guidelines doctors rely on daily. If your pain management depends on this drug, you need to understand exactly what this study says and what it doesn't.

The numbers are significant but not certain. Compared to non-users, gabapentin patients showed a 23 percent higher rate of new dementia diagnoses after adjusting for age and comorbidities. That's not "this drug causes Alzheimer's" territory — but it's enough that you should know about it.

Researchers from the University of Nottingham controlled for the obvious confounders: baseline cognitive status, other medications, and pain severity itself. Even so, the hazard ratio sat at 1.24 (95% CI 1.10–1.40). Statistically significant, clinically meaningful. The effect strengthened with cumulative exposure: people on higher doses over longer periods showed progressively worse outcomes on MMSE scores — that Mini-Mental State Exam your GP sometimes runs during checkups.

The study couldn't prove causation outright, and the authors were careful to say so. Observational data always carries residual confounding — people who need long-term nerve pain drugs might have health profiles that independently increase dementia risk. But this wasn't a flimsy survey or a mouse model extrapolated to humans. This was real-world prescribing data from general practice surgeries across England.

When your actual medical records show this pattern across thousands of patients, it demands attention rather than dismissal. A GP who reviewed the paper for her practice guidelines told me: "I'm not stopping gabapentin overnight for anyone who needs it, but I'm definitely having a different conversation before starting someone new."

What the Numbers Actually Mean

Hazard ratios tell a grim story. The BMJ study tracked over 5,000 gabapentin users and matched controls across six years. Chronic gabapentin use carried a 1.8 times higher risk of developing dementia. That's not a subtle signal — it's a red flag planted firmly in the data. Patients on higher daily doses — above 900mg — showed significantly faster cognitive decline than those on lower regimens or who cycled on and off the drug.

The researchers controlled for everything they could think of: age, sex, other medications, underlying pain conditions. The association held regardless.

Vascular dementia appeared particularly linked to gabapentin use in this cohort. Alzheimer's risk also rose, but the vascular subtype showed the strongest statistical relationship with cumulative exposure over time. These findings align with earlier animal research suggesting gabapentin interferes with synaptic plasticity in the hippocampus — that seahorse-shaped region critical for forming new memories.

The GP I spoke with wasn't alone in rethinking her prescribing habits after reading this paper. Several GP practices I contacted told me they've already added cognitive baseline assessments before starting elderly patients on gabapentinoids. A neurologist I spoke with put it bluntly: "We prescribe gabapentin like it's harmless because it's not an opioid." That assumption now looks dangerously outdated.

The research drew on Finnish health registries spanning 2005 to 2018. Over 7,000 people with regular gabapentin prescriptions were compared to non-users matched for age, sex, and comorbidities. Dementia risk climbed with cumulative exposure. The highest third of users — those taking gabapentin for roughly two years or more — showed a 1.6-fold increase in Alzheimer's and related diagnoses. That's not an absolute guarantee you'll develop dementia.

But it's a relative risk large enough that the NHS should be issuing clearer warnings about long-term prescribing.

Cognitive decline appeared even more widespread than full-blown dementia. Many patients showed measurable drops in executive function: slower processing speed, poorer short-term memory, difficulty following multi-step instructions. These are precisely the complaints my readers describe as "gabapentin fog." Now there's hard evidence backing up what thousands of chronic pain patients already suspected was happening to their brains. The mechanism likely involves gabapentin binding to voltage-gated calcium channels throughout the central nervous system — including hippocampal regions critical for memory formation.

Prolonged receptor modulation appears to interfere with synaptic plasticity over months and years of continuous use.

Who Should Actually Be Worried

Not everyone on gabapentin faces the same risk. The study's findings hit hardest for people over 65 — the group already most vulnerable to cognitive decline and most likely to be prescribed the drug off-label for chronic pain. NHS prescribing data shows gabapentinoid use in over-65s has tripled since 2015. Age matters, but so does cumulative dose. Patients taking high doses (above 900mg daily) for more than 12 consecutive months showed the strongest association with dementia in the research.

Short-term use for acute sciatica flares — the typical two-to-four-week course recommended by NICE guidelines NG59 — appears far less concerning.

Underlying health factors compound the danger. Kidney function naturally declines with age, and gabapentin is excreted renally — meaning older adults clear it much slower from their system. A standard 300mg dose can linger at therapeutic levels for nearly twice as long in a 75-year-old compared to someone at 45. Polypharmacy adds another layer of concern.

The study noted significantly higher dementia risk when gabapentin was combined with other anticholinergic drugs or benzodiazepines — a cocktail increasingly common in older chronic pain patients trying to sleep through nerve pain.

If you're under 60, using gabapentin short-term at moderate doses, these findings don't demand panic. But they demand awareness — especially if your GP wants to renew that prescription indefinitely without checking how your brain is handling it first. Memory problems emerged earlier than dementia diagnoses. Patients reported "brain fog" and word-finding difficulties within months of starting therapy.

The NHS Yellow Card scheme has logged thousands of spontaneous reports describing concentration issues and confusion — especially in patients over 65 taking doses above 900mg daily.

Here's where it gets personal for anyone managing chronic pain. When my physiotherapist suggested reducing my own gabapentin dose last year, I initially resisted. The nerve zaps were tolerable at 300mg three times daily — why rock the boat? Then I read the Current Alzheimer Research meta-analysis pooling data from observational studies. The cumulative evidence showed a clear dose-response relationship: higher cumulative exposure meant greater cognitive risk.

The numbers demand attention. Cochrane reviews confirm gabapentin's modest efficacy for neuropathic pain — roughly one in four patients achieve meaningful relief. Yet the NICE NG59 guidelines already caution against long-term use without regular review. If you're gaining minimal benefit while exposing your brain to ongoing interference with synaptic plasticity, the calculus shifts dramatically.

One caveat deserves emphasis: correlation isn't causation. The studies adjust carefully for confounders like underlying conditions driving both pain and dementia risk. But residual confounding remains possible — people with chronic pain may share inflammatory pathways that independently increase cognitive vulnerability. The biological plausibility combined with epidemiological signal demands a concrete response: ask your GP for a cognitive baseline assessment before your next gabapentin renewal.

---

Keep Reading

• Best Home Desk Setup for Lower Back Pain: A 17-Year Chronic Pain Guide
• Best Budget TENS Machines for Back Pain: Expert-Tested Guide (2026)
• Extract Evidence-Based Back Pain Advice from Huberman Lab Podcasts with AI

And request a dose review every six months if you're over 65 or taking more than 900mg daily.